Login
Login     |     Register     |     Recover Username/Password

General Investing

Oracle Corp. (OCRL) Grows Recurring-Revenue in Enterprise Software

December 05, 2012

Oracle Corp. (ORCL) is the largest enterprise software company and currently has about 50% of its revenues in a fully recurrent mode, selling updates on current software licenses it installs and selling a significant among of product-support services at highly profitable and recurring levels, making it part of the investment portfolio of said Jean-Baptiste Nadal, Managing Director & Lead Portfolio Manager-Global and International at Metropolitan West Capital Management, LLC.

“The company is the market leader in the database market with 50% share, a market with high barriers of entry and extremely high barriers of exit for the clients. Indeed, once Oracle’s products are installed on a client’s system, it’s very difficult to displace them and for the client to switch to another vendor,” Nadal said.

Nadal says enterprise software is among the fastest growing in the technology sector, and he expects ORCL to maintain its position of leadership in enterprise software for the foreseeable future, and the stock is currently near the top in terms of percentage of his portfolio holdings.

“From a catalyst standpoint, we think that the company will continue to broaden its product portfolio in part through bold acquisitions, so to become the vendor of choice for most corporations. Therefore, we believe that the competitive position of the company is actually strengthening and its ability to generate strong cash flow over a long period of time is pretty much intact,” Nadal said.


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now